Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 68.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,370 shares of the medical research company’s stock after purchasing an additional 2,587 shares during the period. Aptus Capital Advisors LLC’s holdings in Edwards Lifesciences were worth $441,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Truvestments Capital LLC boosted its holdings in Edwards Lifesciences by 260.0% in the second quarter. Truvestments Capital LLC now owns 270 shares of the medical research company’s stock worth $25,000 after purchasing an additional 195 shares in the last quarter. Castleview Partners LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. Compass Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 4th quarter worth approximately $31,000. Northwest Capital Management Inc acquired a new position in Edwards Lifesciences during the second quarter valued at approximately $34,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $38,000. 79.25% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $74.62, for a total transaction of $2,190,097.00. Following the sale, the director now owns 4,486 shares in the company, valued at $334,745.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $70.00, for a total transaction of $245,000.00. Following the completion of the transaction, the vice president now owns 23,950 shares of the company’s stock, valued at approximately $1,676,500. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $74.62, for a total transaction of $2,190,097.00. Following the completion of the sale, the director now owns 4,486 shares in the company, valued at $334,745.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 139,339 shares of company stock valued at $10,324,578. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $85.01 on Friday. The business has a 50 day simple moving average of $75.71 and a 200 day simple moving average of $73.47. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.45. The company has a market capitalization of $51.56 billion, a PE ratio of 36.96, a price-to-earnings-growth ratio of 4.27 and a beta of 1.04. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $94.87.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period last year, the business earned $0.64 earnings per share. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. Leerink Partnrs reissued a “market perform” rating on shares of Edwards Lifesciences in a research report on Monday, October 16th. Citigroup downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Monday, December 11th. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $57.00 price target on the stock. in a research report on Tuesday, November 28th. Morgan Stanley increased their price objective on Edwards Lifesciences from $80.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $87.38.

Check Out Our Latest Research Report on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.